Su Mei-Chi, Nethi Susheel Kumar, Dhanyamraju Pavan Kumar, Prabha Swayam
Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.
Nanovaccine Institute, Department of Chemical & Biological Engineering, Iowa State University, Ames, IA 50011, USA.
Cancers (Basel). 2023 Aug 17;15(16):4145. doi: 10.3390/cancers15164145.
The tumor stroma, or the microenvironment surrounding solid tumors, can significantly impact the effectiveness of cancer therapies. The tumor microenvironment is characterized by high interstitial pressure, a consequence of leaky vasculature, and dense stroma created by excessive deposition of various macromolecules such as collagen, fibronectin, and hyaluronic acid (HA). In addition, non-cancerous cells such as cancer-associated fibroblasts (CAFs) and the extracellular matrix (ECM) itself can promote tumor growth. In recent years, there has been increased interest in combining standard cancer treatments with stromal-targeting strategies or stromal modulators to improve therapeutic outcomes. Furthermore, the use of nanomedicine, which can improve the delivery and retention of drugs in the tumor, has been proposed to target the stroma. This review focuses on how different stromal components contribute to tumor progression and impede chemotherapeutic delivery. Additionally, this review highlights recent advancements in nanomedicine-based stromal modulation and discusses potential future directions for developing more effective stroma-targeted cancer therapies.
肿瘤基质,即实体瘤周围的微环境,可显著影响癌症治疗的效果。肿瘤微环境的特征是间质压力高,这是血管渗漏的结果,以及由胶原蛋白、纤连蛋白和透明质酸(HA)等各种大分子过度沉积形成的致密基质。此外,诸如癌症相关成纤维细胞(CAF)和细胞外基质(ECM)本身等非癌细胞可促进肿瘤生长。近年来,人们越来越有兴趣将标准癌症治疗与基质靶向策略或基质调节剂相结合,以改善治疗效果。此外,有人提出使用纳米药物来靶向基质,纳米药物可改善药物在肿瘤中的递送和滞留。本综述重点关注不同的基质成分如何促进肿瘤进展并阻碍化疗药物递送。此外,本综述强调了基于纳米药物的基质调节的最新进展,并讨论了开发更有效的基质靶向癌症治疗的潜在未来方向。